Scilex Holding Company (SCLX) Debt Components
- 2026-06-30: Debt, CurrentUSD $80.81M; Senior NotesUSD $28.77M; Line of Credit Facility, Interest Rate at Period Endpure 5.39%; Debt Instrument Issued PrincipalUSD (m).
- 2026-03-31: Debt, CurrentUSD $80.78M; Senior NotesUSD $28.86M; Line of Credit Facility, Interest Rate at Period Endpure 5.39%; Debt Instrument Issued PrincipalUSD (m).
- 2025-12-31: Debt, CurrentUSD $83.26M; Senior NotesUSD $27.69M; Line of Credit Facility, Interest Rate at Period Endpure (m); Debt Instrument Issued PrincipalUSD (m).
- 2025-12-31: Debt, CurrentUSD (m); Senior NotesUSD (m); Line of Credit Facility, Interest Rate at Period Endpure 5.39%; Debt Instrument Issued PrincipalUSD (m).
Scilex Holding Company Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Debt, Current USD | Senior Notes USD | Line of Credit Facility, Interest Rate at Period End pure | Debt Instrument Issued Principal USD | Short-term Debt USD | Long-term Debt USD | Commercial Paper, at Carrying Value USD | Debt Instrument, Face Amount USD | Debt Instrument, Fair Value Disclosure USD | Debt Instrument, Periodic Payment, Principal USD | Debt Instrument, Annual Principal Payment USD | Debt Instrument, Convertible, Conversion Price USD/shares | Debt Instrument, Unamortized Discount USD | Notes Payable, Related Parties, Current USD | Notes Payable, Related Parties, Noncurrent USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $80.81M | $28.77M | 5.39% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $80.78M | $28.86M | 5.39% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $83.26M | $27.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | 5.39% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $45.67M | $24.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $39.87M | $18.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $39.44M | $14.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $34.88M | $12.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $84.64M | $69.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $75.37M | $75.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $92.92M | $92.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $108.43M | $104.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 8.00 | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | 9 month · $25.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $115.22M | $106.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 8.00 | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | 6 month · $25.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-04-30 | (m) | (m) | (m) | $25.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $106.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | $0.00 |
| 2022-04-18 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $500.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-04-11 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $9.44K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $45.90M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $29.14M | (m) | (m) | (m) | $37.95M | $72.04M | $101.17M | (m) | $115.40M | (m) | $134.00M | (m) | $30.60M | $19.61M | $23.50M |
| 2021-12-20 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $500.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $69.80M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $125.00K | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |